4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy […]
